Pentosan Polysulfate Inhibits Attachment and Infection by SARS-CoV-2 In Vitro: Insights into Structural Requirements for Binding

 

 Buy Article Permissions and Reprints

Abstract

Two years since the outbreak of the novel coronavirus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) pandemic, there remain few clinically effective drugs to complement vaccines. One is the anticoagulant, heparin, which in 2004 was found able to inhibit invasion of SARS-CoV (CoV-1) and which has been employed during the current pandemic to prevent thromboembolic complications and moderate potentially damaging inflammation. Heparin has also been shown experimentally to inhibit SARS-CoV-2 attachment and infection in susceptible cells. At high therapeutic doses however, heparin increases the risk of bleeding and prolonged use can cause heparin-induced thrombocytopenia, a serious side effect. One alternative, with structural similarities to heparin, is the plant-derived, semi-synthetic polysaccharide, pentosan polysulfate (PPS). PPS is an established drug for the oral treatment of interstitial cystitis, is well-tolerated, and exhibits weaker anticoagulant effects than heparin. In an established Vero cell model, PPS and its fractions of varying molecular weights inhibited invasion by SARS-CoV-2. Intact PPS and its size-defined fractions were characterized by molecular weight distribution and chemical structure using nuclear magnetic resonance spectroscopy and liquid chromatography–mass spectrometry, then employed to explore the structural basis of interactions with SARS-CoV-2 spike protein receptor-binding domain (S1 RBD) and the inhibition of Vero cell invasion. PPS was as effective as unfractionated heparin, but more effective in inhibiting cell infection than low-molecular-weight heparin (on a weight/volume basis). Isothermal titration calorimetry and viral plaque-forming assays demonstrated size-dependent binding to S1 RBD and inhibition of Vero cell invasion, suggesting the potential application of PPS as a novel inhibitor of SARS-CoV-2 infection.

^* Joint first authors.

^** Senior authors.

Publication History

Received: 03 January 2021

Accepted: 03 March 2022

Accepted Manuscript online:
23 March 2022

Article published online:
04 July 2022

© 2022. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

• References

• 1 Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 2021; 19 (03) 141-154
  CrossrefPubMedGoogle Scholar
• 2 Beigel JH, Tomashek KM, Dodd LE. et al; ACTT-1 Study Group Members. Remdesivir for the treatment of Covid-19 - final report. N Engl J Med 2020; 383 (19) 1813-1826
  CrossrefPubMedGoogle Scholar
• 3 Koirala J, Gyanwali P, Gerzoff RB. et al; Nepal COVID-19 Clinical Study Collaborators. Experience of treating COVID-19 with Remdesivir and convalescent plasma in a resource-limited setting: a prospective, observational study. Open Forum Infect Dis 2021; 8 (08) b391
  CrossrefPubMedGoogle Scholar
• 4 Gordon CJ, Tchesnokov EP, Schinazi RF, Götte M. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. J Biol Chem 2021; 297 (01) 100770
  CrossrefPubMedGoogle Scholar
• 5 Kabinger F, Stiller C, Schmitzová J. et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol 2021; 28 (09) 740-746
  CrossrefPubMedGoogle Scholar
• 6 Mycroft-West CJ, Su D, Pagani I. et al. Heparin inhibits cellular invasion by SARS-CoV-2: structural dependence of the interaction of the spike S1 receptor-binding domain with heparin. Thromb Haemost 2020; 120 (12) 1700-1715
  Article in Thieme ConnectPubMedGoogle Scholar
• 7 Clausen TM, Sandoval DR, Spliid CB. et al. SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2. Cell 2020; 183 (04) 1043-1057
  CrossrefPubMedGoogle Scholar
• 8 Vicenzi E, Canducci F, Pinna D. et al. Coronaviridae and SARS-associated coronavirus strain HSR1. Emerg Infect Dis 2004; 10 (03) 413-418
  CrossrefPubMedGoogle Scholar
• 9 Nahmias AJ, Kibrick S. Inhibitory effect of heparin on herpes simplex virus. J Bacteriol 1964; 87 (05) 1060-1066
  CrossrefPubMedGoogle Scholar
• 10 Skidmore MA, Kajaste-Rudnitski A, Wells NM. et al. Inhibition of influenza H5N1 invasion by modified heparin derivatives. MedChemComm 2015; 6: 640-646
  CrossrefPubMedGoogle Scholar
• 11 Germi R, Crance JM, Garin D. et al. Heparan sulfate-mediated binding of infectious dengue virus type 2 and yellow fever virus. Virology 2002; 292 (01) 162-168
  CrossrefPubMedGoogle Scholar
• 12 Ghezzi S, Cooper L, Rubio A. et al. Heparin prevents Zika virus induced-cytopathic effects in human neural progenitor cells. Antiviral Res 2017; 140: 13-17
  CrossrefPubMedGoogle Scholar
• 13 Tandon R, Sharp JS, Zhang F. et al. Effective inhibition of SARS-CoV-2 entry by heparin and enoxaparin derivatives. J Virol 2021; 95 (03) 1-12
  CrossrefPubMedGoogle Scholar
• 14 Parisi R, Costanzo S, Di Castelnuovo A, de Gaetano G, Donati MB, Iacoviello L. Different anticoagulant regimens, mortality, and bleeding in hospitalized patients with COVID-19: a systematic review and an updated meta-analysis. Semin Thromb Hemost 2021; 47 (04) 372-391
  Google Scholar
• 15 Cuker A, Tseng EK, Nieuwlaat R. et al. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Adv 2021; 5 (03) 872-888
  CrossrefPubMedGoogle Scholar
• 16 Schuurs ZP, Hammond E, Elli S. et al. Evidence of a putative glycosaminoglycan binding site on the glycosylated SARS-CoV-2 spike protein N-terminal domain. Comput Struct Biotechnol J 2021; 19: 2806-2818
  CrossrefPubMedGoogle Scholar
• 17 Kwon PS, Oh H, Kwon SJ. et al. Sulfated polysaccharides effectively inhibit SARS-CoV-2 in vitro. Cell Discov 2020; 6 (01) 50
  CrossrefPubMedGoogle Scholar
• 18 Nie C, Pouyan P, Lauster D. et al. Polysulfates block SARS-CoV-2 uptake through electrostatic interactions. Angew Chem Int Ed Engl 2021; 60 (29) 15870-15878
  CrossrefPubMedGoogle Scholar
• 19 Alekseeva A, Raman R, Eisele G. et al. In-depth structural characterization of pentosan polysulfate sodium complex drug using orthogonal analytical tools. Carbohydr Polym 2020; 234: 115913
  CrossrefPubMedGoogle Scholar
• 20 Sanden C, Mori M, Jogdand P. et al. Broad Th2 neutralization and anti-inflammatory action of pentosan polysulfate sodium in experimental allergic rhinitis. Immun Inflamm Dis 2017; 5 (03) 300-309
  CrossrefPubMedGoogle Scholar
• 21 Fellstrom B, Bjorklund U, Danielson BG. et al. Pertosan polysulfate (ELMIRON®): pharmacokinetics and effects on the urinary inhibition of crystal growth. In: Vahlensieck W, Gassner G, eds. Pathogenese und Klinik der Harnsteine. Darmstadt:: Steinkopff-Verlag;; 1987: 340-396
  Google Scholar
• 22 Simon M, McClanahan RH, Shah JF, Repko T, Modi NB. Metabolism of [3H]pentosan polysulfate sodium (PPS) in healthy human volunteers. Xenobiotica 2005; 35 (08) 775-784
  CrossrefPubMedGoogle Scholar
• 23 Erickson DR, Sheykhnazari M, Bhavanandan VP. Molecular size affects urine excretion of pentosan polysulfate. J Urol 2006; 175 (3, Pt 1): 1143-1147
  CrossrefPubMedGoogle Scholar
• 24 Mulholland SG, Hanno P, Parsons CL, Sant GR, Staskin DR. Pentosan polysulfate sodium for therapy of interstitial cystitis. A double-blind placebo-controlled clinical study. Urology 1990; 35 (06) 552-558
  CrossrefPubMedGoogle Scholar
• 25 Bisio A, Mantegazza A, Vecchietti D. et al. Determination of the molecular weight of low-molecular-weight heparins by using high-pressure size exclusion chromatography on line with a triple detector array and conventional methods. Molecules 2015; 20 (03) 5085-5098
  CrossrefPubMedGoogle Scholar
• 26 Bertini S, Risi G, Guerrini M, Carrick K, Szajek AY, Mulloy B. Molecular weights of bovine and porcine heparin samples: comparison of chromatographic methods and results of a collaborative survey. Molecules 2017; 22 (07) 1214
  CrossrefPubMedGoogle Scholar
• 27 Guerrini M, Naggi A, Guglieri S, Santarsiero R, Torri G. Complex glycosaminoglycans: profiling substitution patterns by two-dimensional nuclear magnetic resonance spectroscopy. Anal Biochem 2005; 337 (01) 35-47
  Google Scholar
• 28 Mauri L, Boccardi G, Torri G. et al. Qualification of HSQC methods for quantitative composition of heparin and low molecular weight heparins. J Pharm Biomed Anal 2017; 136: 92-105
  Google Scholar
• 29 Kreimann M, Brandt S, Krauel K. et al. Binding of anti-platelet factor 4/heparin antibodies depends on the thermodynamics of conformational changes in platelet factor 4. Blood 2014; 124 (15) 2442-2449
  CrossrefPubMedGoogle Scholar
• 30 Robinson CJ, Harmer NJ, Goodger SJ, Blundell TL, Gallagher JT. Cooperative dimerization of fibroblast growth factor 1 (FGF1) upon a single heparin saccharide may drive the formation of 2:2:1 FGF1.FGFR2c.heparin ternary complexes. J Biol Chem 2005; 280 (51) 42274-42282
  CrossrefPubMedGoogle Scholar
• 31 Vo Y, Schwartz BD, Onagi H. et al. A rapid and mild sulfation strategy reveals conformational preferences in therapeutically relevant sulfated Xylooligosaccharides. Chemistry 2021; 27 (38) 9830-9838
  CrossrefPubMedGoogle Scholar
• 32 Maruyama T, Toida T, Imanari T, Yu G, Linhardt RJ. Conformational changes and anticoagulant activity of chondroitin sulfate following its O-sulfonation. Carbohydr Res 1998; 306 (1-2): 35-43
  CrossrefPubMedGoogle Scholar
• 33 Uniewicz KA, Ori A, Xu R. et al. Differential scanning fluorimetry measurement of protein stability changes upon binding to glycosaminoglycans: a screening test for binding specificity. Anal Chem 2010; 82 (09) 3796-3802
  CrossrefPubMedGoogle Scholar
• 34 Lima MA, Hughes AJ, Veraldi N. et al. Antithrombin stabilisation by sulfated carbohydrate s correlates with anticoagulant activity. MedChemComm 2013; 4 (05) 870-873
  CrossrefPubMedGoogle Scholar
• 35 Antonelli M, Penfold RS, Merino J. et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis 2022; 22 (01) 43-55
  CrossrefPubMedGoogle Scholar
• 36 van Haren FMP, Page C, Laffey JG. et al. Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence. Crit Care 2020; 24 (01) 454
  CrossrefPubMedGoogle Scholar
• 37 Rentsch CT, Beckman JA, Tomlinson L. et al. Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study. BMJ 2021; 372 (311) n311
  CrossrefPubMedGoogle Scholar
• 38 Soria C, Soria J, Ryckewaert JJ, Holmer E, Caen JP. Anticoagulant activities of a pentosane polysulphate: comparison with standard heparin and a fraction of low molecular weight heparin. Thromb Res 1980; 19 (4–5): 455-463
  CrossrefPubMedGoogle Scholar
• 39 Vinazzer H, Haas S, Stemberger A. Influence on the clotting mechanism of sodium pentosan polysulfate (SP54) in comparison to commercial beef lung sodium heparin. Thromb Res 1980; 20 (01) 57-68
  CrossrefPubMedGoogle Scholar
• 40 Stringer SE, Gallagher JT. Specific binding of the chemokine platelet factor 4 to heparan sulfate. J Biol Chem 1997; 272 (33) 20508-20514
  CrossrefPubMedGoogle Scholar
• 41 Berglund J, Angles d'Ortoli T, Vilaplana F. et al. A molecular dynamics study of the effect of glycosidic linkage type in the hemicellulose backbone on the molecular chain flexibility. Plant J 2016; 88 (01) 56-70
  CrossrefPubMedGoogle Scholar
• 42 Magden J, Kääriäinen L, Ahola T. Inhibitors of virus replication: recent developments and prospects. Appl Microbiol Biotechnol 2005; 66 (06) 612-621
  CrossrefPubMedGoogle Scholar
• 43 van Haren FMP, Laffey JG, Artigas A. et al; CHARTER Collaborative Research Group. Can nebulised HepArin Reduce morTality and time to Extubation in patients with COVID-19 Requiring invasive ventilation Meta-Trial (CHARTER-MT): protocol and statistical analysis plan for an investigator-initiated international meta-trial of prospective randomised clinical studies. Br J Clin Pharmacol 2022; DOI: 10.1111/bcp.15253.
  CrossrefPubMedGoogle Scholar
• 44 Ramacciotti E, Clark M, Sadeghi N. et al. Review: contaminants in heparin: review of the literature, molecular profiling, and clinical implications. Clin Appl Thromb Hemost 2011; 17 (02) 126-135
  CrossrefPubMedGoogle Scholar
• 45 Guerrini M, Zhang Z, Shriver Z. et al. Orthogonal analytical approaches to detect potential contaminants in heparin. Proc Natl Acad Sci U S A 2009; 106 (40) 16956-16961
  CrossrefPubMedGoogle Scholar

• Supplementary Material